Kedudukan dalam Saham
#38628
Poolbeg Pharma plc is a clinical-stage biopharmaceutical company based in the... Poolbeg Pharma plc is a clinical-stage biopharmaceutical company based in the United Kingdom, focused on developing treatments for infectious diseases. Its pipeline features several key programs: POLB 001, a p38 MAP Kinase inhibitor intended for severe influenza; POLB 002, a pioneering, in-licensed RNA-based immunotherapy administered intranasally to combat respiratory virus infections; and POLB 003, an intramuscular vaccine aimed at preventing Melioidosis. Beyond specific therapeutic candidates, Poolbeg also holds licensed access to advanced micro- and nanoencapsulation technology for an oral vaccine delivery system designed to stimulate gut immunity. The company further advances its research through an artificial intelligence-powered drug program. Additionally, Poolbeg is developing a biomarker platform to identify individuals at high risk of severe disease, alongside a model-derived vaccine discovery platform to pinpoint novel vaccine candidates. Incorporated in 2021, Poolbeg Pharma plc is headquartered in London.
Perubahan (1 hari)
-2.30%
Perubahan (1 tahun)
189.81%
Perdagangan Poolbeg Pharma PLC (POLB)
Harga POLB dengan permodalan pasaran b
Modal pasaran bagi Poolbeg Pharma PLC(POLB)
Modal Pasaran: $882.99K
Sehingga August 2026, Poolbeg Pharma PLC mempunyai modal pasaran sebanyak $882.99K. Ini menjadikan Poolbeg Pharma PLC syarikat ke-38628th paling bernilai di dunia mengikut data kami. Kapitalisasi pasaran ialah nilai keseluruhan saham syarikat tersenarai yang berada dalam edaran dan lazimnya digunakan untuk menilai nilai syarikat tersebut.
Sejarah modal pasaran Poolbeg Pharma PLC dari 2021 hingga 2026
POLB berbanding dengan 5 teratas yang paling popular stocks
| Harga POLB |
|
Aset B |
Pasaran B |
Hasilnya |
|
|
|
|
$5.457T
|
+617,959,026.73%
|
|
|
|
|
$4.483T
|
+507,738,036.93%
|
|
|
|
|
$4.161T
|
+471,292,844.65%
|
|
|
|
|
$3.687T
|
+417,530,730.81%
|
|
|
|
|
$2.835T
|
+321,023,788.21%
|
